ProMIS Neurosciences Inc. filings document a clinical-stage biotechnology issuer with common shares listed on the Nasdaq Capital Market and organized in Ontario, Canada. Formal disclosures cover PMN310 and related clinical or regulatory updates, operating results, financing arrangements, registered security status, and the company’s capital structure, including common shares, purchase warrants, pre-funded warrants, and share consolidation actions.
Proxy and 8-K filings record shareholder voting matters, director elections, independent auditor ratification, equity incentive plan proposals, board appointments, and other governance changes. The filing record also documents Nasdaq listing compliance matters, material definitive agreements, and financial condition disclosures connected to the company’s neurodegenerative-disease development programs.
ProMIS Neurosciences Inc. is reported to have 7.66% of its common shares beneficially owned by Great Point Partners, LLC together with Dr. Jeffrey R. Jay, M.D. and Ms. Lillian Nordahl, acting as a group. This beneficial ownership covers 736,881 common shares, including shares underlying certain warrants, with all voting and dispositive power held on a shared basis and no sole power reported.
The 7.66% figure is calculated against 9,618,424 shares of common stock deemed outstanding, consisting of 8,967,693 shares outstanding as of the company’s latest quarterly report plus 650,731 shares issuable upon exercise of warrants held by the reporting persons, subject to a 9.99% Beneficial Ownership Cap. The positions are held through Biomedical Value Fund, L.P. and Biomedical Offshore Value Fund, Ltd., for which Great Point serves as investment manager, and Dr. Jay and Ms. Nordahl may be deemed beneficial owners, while each disclaims ownership beyond any pecuniary interest.
Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. filed an amended ownership report for ProMIS Neurosciences, Inc. common stock. The fund reports beneficial ownership of 696,378 shares, representing 7.77% of the class. All of these shares are held with shared voting and shared dispositive power, with no sole voting or dispositive authority reported. The reporting person is organized in the Cayman Islands, with its principal business office in Boston, Massachusetts, and files this as Amendment No. 1 to its Schedule 13G.
ProMIS Neurosciences Inc., a clinical-stage biotechnology company focused on antibody therapeutics for neurodegenerative diseases, reported second quarter 2026 results and updated progress on its lead Alzheimer’s candidate PMN310. The company highlighted blinded six-month interim safety and biomarker data from PRECISE-AD, its Phase 1b trial in early Alzheimer’s disease, noting that across 136 safety‑evaluable participants and all APOE genotypes, no cases of ARIA‑E were observed. The blinded analysis also showed early, directionally consistent changes in plasma pTau217 and CSF MTBR‑tau243.
Management stated that PMN310 targets toxic amyloid‑beta oligomers while avoiding plaque and may therefore reduce ARIA risk and potentially improve efficacy compared with plaque‑directed antibodies. Twelve‑month unblinded topline results from PRECISE‑AD, including cognitive outcomes, are expected in the first quarter of 2027. ProMIS ended June 30, 2026 with $53.4 million in cash and short‑term investments and reported total current assets of $56.7 million and shareholders’ equity of $49.4 million, which management believes provide runway through 2027. For the quarter, operating expenses were $12.3 million and the net loss was $11.7 million, compared with $10.2 million and $10.1 million respectively a year earlier.
ProMIS Neurosciences Inc. reported a net loss of $11.7 million for the quarter and $20.0 million for the six months ended June 30, 2026, compared with losses of $10.1 million and $17.5 million in 2025. Operating expenses rose as the company advanced its lead Alzheimer’s antibody PMN310 and expanded its organization.
R&D spending reached $16.5 million for the first half of 2026, driven mainly by the Phase 1b PRECISE-AD trial, while G&A expenses increased to $4.4 million on higher compensation and professional fees. A January 2026 private placement provided $70.1 million of net proceeds, lifting cash to $53.4 million and total assets to $56.7 million with minimal liabilities of $7.3 million, resulting in positive shareholders’ equity of $49.4 million.
Management expects existing cash and short-term investments to fund operations and capital needs through 2027, while acknowledging continued losses and the need for additional capital to support future clinical activities beyond the current plan.
ProMIS Neurosciences, Inc. has a Schedule 13G/A filed by several Wellington entities reporting a passive ownership position in the company’s common stock as of June 30, 2026. Wellington Management Group LLP and related holding and advisory entities report beneficial ownership of 696,378 shares of ProMIS common stock, representing 7.77% of the class. The Wellington entities report no sole voting or dispositive power, but shared voting and shared dispositive power over all 696,378 shares. The shares are held of record by clients of one or more Wellington investment advisers, including certain Wellington Biomedical Innovation Master Investors funds that may each hold more than five percent of the class at the client level.
Johanne Kaplan, Chief Development Officer of ProMIS Neurosciences Inc., purchased 2,280 Common Shares on August 5, 2026 in a purchase classified as an open market or private transaction at $13.30 per share. After this transaction, Kaplan directly owns 6,221 Common Shares of the company.
ProMIS Neurosciences Inc. reported blinded six-month interim safety and biomarker data from PRECISE-AD, its Phase 1b trial of PMN310 in early Alzheimer’s disease. In 136 patients, PMN310 showed a favorable safety profile across all genotypes with no ARIA-E cases observed as of the data cutoff, and ARIA-H tracking background rates.
The interim readout also showed early, directionally consistent movement in disease-relevant biomarkers, including plasma pTau217 and CSF MTBR-tau243, suggesting target engagement, while the study remains blinded. PRECISE-AD has enrolled 144 participants receiving multiple intravenous doses of 5, 10, or 20 mg/kg for 12 months, with topline 12-month results expected in the first quarter of 2027. PMN310 is a humanized IgG1 antibody designed to selectively target toxic amyloid-beta oligomers and was granted FDA Fast Track Designation in July 2025.
ProMIS Neurosciences Inc. director William W. Wyman received two option awards to buy Common Shares. One grant covers 11,000 options at an exercise price of $10.77 per share, expiring on May 20, 2036. A second grant covers 5,500 options on the same terms.
According to the footnotes, one grant vests in full on May 20, 2027, while another vests with 25% upon grant and the remainder ratably over thirty-six months, in each case subject to continued service on the Board.
ProMIS Neurosciences Inc. director Eugene Williams reported receiving two option grants to buy common shares. On May 20, 2026, he was awarded options for 11,000 shares and 5,500 shares, each with an exercise price of $10.77 per share and expiring on May 20, 2036.
According to the footnotes, the 11,000-share option vests in full on May 20, 2027, subject to his continued service on the board. For the 5,500-share option, 25% vested upon grant and the remaining shares vest ratably over 36 months, also conditioned on continued board service. These are compensation-related awards, not open‑market purchases.
ProMIS Neurosciences Inc. reported that Chief Executive Officer Neil K. Warma received a grant of stock options. The award covers 160,000 options to buy common shares at an exercise price of $10.77 per share, expiring on May 20, 2036. According to the footnote, these options vest ratably over four years, contingent on his continued service with the company.